Table 5. Univariate and multivariate analyses of overall survival after disease progression during second-line therapy.

	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Second-line chemotherapy regimen
FOLFIRI	1	-	-	1	-	-
FOLFOX	0.966	0.677–1.379	0.848	1.082	0.748–1.565	0.675
Second-line continued cetuximab
No	1	-	-	1	-	-
Yes	0.585	0.407–0.841	0.004*	0.663	0.454–0.969	0.034*
Second-line maintenance treatment
No	1	-	-	1	-	-
Yes	0.491	0.274–0.881	0.017*	0.745	0.389–1.425	0.373
Following TACE/TAI for metastases
No	1	-	-	1	-	-
Yes	0.704	0.464–1.067	0.098	0.886	0.570–1.376	0.589
Following Radiofrequency for metastases
No	1	-	-	1	-	-
Yes	1.328	0.746–2.364	0.336	1.278	0.735–2.220	0.385
Following Radiotherapy for metastases
No	1	-	-	1	-	-
Yes	1.028	0.565–1.870	0.928	1.139	0.615–2.109	0.678
Following chemotherapy
Best support care	1	-	-	1	-	-
Intensive chemotherapy§	0.437	0.233–0.816	0.009*	0.417	0.219–0.792	0.008*
Following bevacizumab
No	1	-	-	1	-	-
Yes	0.564	0.351–0.906	0.018*	0.644	0.391–1.060	0.084

HR: hazard ratio; CI: confidence interval; TACE: transcatheter arterial chemoembolization; TAI: transcatheter arterial infusion.

^§Intensive chemotherapy: receiving at least one intravenous chemotherapy medicine.

P values were calculated using Cox regression.

Bold font for P < 0.10;

^*for P < 0.05.